Zhitong Financial App News, Jiankai Technology (688356.SH) issued a stock price change announcement stating that on August 19, MSD and Moderna announced that IntiSmeran (MRNA-4157/v940) and KeyTruda had reached the main endpoint RFS and the key secondary endpoint DMFS in phase III Interpath-001 (n=1,137) for adjuvant treatment of stage IIB-IV melanoma. According to the company's own inspection, the company did not directly supply LNP core raw materials to Moderna. The impact of commercialization of mRNA oncology vaccines on the company's business is mainly reflected in the following two aspects:

Zhitongcaijing · 1d ago
Zhitong Financial App News, Jiankai Technology (688356.SH) issued a stock price change announcement stating that on August 19, MSD and Moderna announced that IntiSmeran (MRNA-4157/v940) and KeyTruda had reached the main endpoint RFS and the key secondary endpoint DMFS in phase III Interpath-001 (n=1,137) for adjuvant treatment of stage IIB-IV melanoma. According to the company's own inspection, the company did not directly supply LNP core raw materials to Moderna. The impact of commercialization of mRNA oncology vaccines on the company's business is mainly reflected in the following two aspects: